Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Radboud University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Radboud University
ClinicalTrials.gov Identifier:
NCT01292681
First received: February 1, 2011
Last updated: September 7, 2011
Last verified: September 2011
  Purpose

Because of metastatic liver cancer of the colon or rectum, patients will be treated with cytotoxic drugs (chemotherapy). In the Radboud University Nijmegen Medical Centre the investigators investigate whether the imaging techniques at an early stage of treatment can predict which patients will have benefited from this treatment.

In the study the investigators use two different scanners: a MR (magnetic resonance) scanner and a PET (Positron Emission Tomography) scanner combined with a CT (Computer Tomography) scanner. An MR scanner is a large magnet and looks like a CT scanner which also makes pictures. But instead of using X-rays the recordings are made with magnetic fields. The scan consists of a table on which the patient will lie with the head in a half-dome with a camera. The examination with the MR scan is not painful and not harmful.

The PET scan is a type of CT scan that makes (after administration of a radioactive liquid), a scan of (part of) the body. The amount of radioactivity that is used for the study is so small that it will not have an adverse impact on the patient. This research is two times combined with a''normal''CT scan.

Using the MR scan, the investigators can research the oxygensupply, the aggressiveness of the tumour and the degree of liver metastases that die from the chemotherapy . The investigators can also, after administration of a MR contrast agent, investigate the blood supply of a tumor through imaging. If you are treated with the chemotherapeutic drug capecitabine the investigators can monitor the intake of this agent in the liver metastases. The PET CT scan tells us more about the metabolism in the liver metastases.


Condition Intervention
Colorectal Cancer
Other: Multi-modality imaging

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Correlation early changes in imaging and treatment outcome [ Time Frame: imaging before start, week 1, week 9 ] [ Designated as safety issue: No ]
    Correlation early changes in imaging and treatment outcome Week -2-0: PET-CT and MRI Week 0 Start chemotherapy Week 1 PET-CT and MRI Week 9 PET-CT onderzoek


Secondary Outcome Measures:
  • Correlation pretreatment imaging values and treatment outcome [ Time Frame: imaging before start, week 1 and week 9 ] [ Designated as safety issue: No ]
    Correlation pretreatment imaging values and treatment outcome Week -2-0: PET-CT and MRI Week 0 Start chemotherapy Week 1 PET-CT and MRI Week 9 PET-CT onderzoek


Estimated Enrollment: 60
Study Start Date: August 2009
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Multi-modality imaging Other: Multi-modality imaging
Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological proven colorectal cancer with histologically proven distant metastases.
  • First line fluoropyrimidine-based treatment for liver metastases of colorectal cancer containing fluoropyrimidines.
  • Measurable liver metastases of at least 2 cm.
  • Age minimal 18 years.
  • Written informed consent

Exclusion Criteria:

  • Prior chemotherapy within six months before start of the study.
  • Contra-indication for MR and/or PET examinations (e.g. pacemaker, claustrophobia, diabetes mellitus).
  • Karnofsky Performance Status <70.
  • Diffuse liver metastases.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01292681

Contacts
Contact: C.J.A. Punt, Md PhD +31 24 361 03 53 c.punt@onco.umcn.nl

Locations
Netherlands
Radboud University Nijmegen Medical Centre Recruiting
Nijmegen, Gelderland, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: C.J.A. Punt, Md PhD Radboud University
  More Information

No publications provided

Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT01292681     History of Changes
Other Study ID Numbers: MICC
Study First Received: February 1, 2011
Last Updated: September 7, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
colorectal cancer
FDG-PET-CT
MRS,
DCE-MRI
DWI
colorectal cancer with histologically proven distant metastases

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on August 21, 2014